8th January 2017
Home » New » A Placebo Controlled Trial Of Oral Fingolimod In Relapsing
A Placebo Controlled Trial Of Oral Fingolimod In Relapsing

A Placebo-Controlled Trial Of Oral Fingolimod In Relapsing - Original Article. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. Ludwig Kappos, M.D., Ernst-Wilhelm Radue, M.D., Paul O'Connor, M.D . Read more ...

A Placebo-Controlled Trial Of Oral Cladribine For - Original Article. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. Gavin Giovannoni, M.B., B.Ch., Ph.D., Giancarlo Comi, M.D., Stuart . Read more ...

No Evidence Of Disease Activity: Indirect Comparisons Of - Results. The estimated relative risks of achieving NEDA status for fingolimod versus placebo in a pooled fingolimod trial population were numerically greater (i.e . Read more ...

Fingolimod - Wikipedia - Fingolimod (INN, trade name Gilenya, Novartis) is an immunomodulating drug, mostly used for treating multiple sclerosis (MS). It has reduced the rate of relapses in . Read more ...

Fingolimod In The Treatment Algorithm Of Relapsing - Fingolimod is the first oral treatment of multiple sclerosis. It is the first-in-class sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phophate . Read more ...

Gilenya (Fingolimod Capsules): Side Effects, Interactions - Learn about Gilenya (Fingolimod Capsules) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.. Read more ...

Multiple Sclerosis - Aetna - Treatment of acute exacerbations of multiple sclerosis (MS) when the acute relapse is characterized by functionally disabling symptoms with documented evidence of . Read more ...

Revised SPC: Gilenya (fingolimod) 0.5mg Hard - Medicines - Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient groups:. Read more ...

Fingolimod – Wikipedia - Fingolimod ist eine chemische Verbindung, die unter dem Handelsname Gilenya als Arzneistoff zur Behandlung von Multipler Sklerose (MS) eingesetzt wird.. Read more ...

Rituximab (Rituxan) - Aetna - Number: 0314. Policy. Aetna considers rituximab (Rituxan) medically necessary for any of the following indications: Acute lymphoid leukemia (induction/consolidation . Read more ...